Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neurofibromatosis 1 9Breast Neoplasms 5Neurofibroma, Plexiform 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Neurofibrosarcoma 3Thyroid Neoplasms 2Neoplasms 2Melanoma 2Gallbladder Neoplasms 2Uveal Melanoma 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Meningioma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × AZD 6244 × Clear all
NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Gallbladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡